The movement toward precision medicine for cancer therapy has been hindered by innate and acquired resistance to targeted therapeutics. Common oncogenes and tumor suppressors act in a signaling network that converges on mTORC1, leading to its aberrant activation in the majority of tumors. While mTOR inhibitors are effective as monotherapies in some tumor settings, such as tuberous sclerosis complex, they are generally not sufficient to achieve antitumor responses in most sporadic cancers.